After treatment with rosiglitazone, a PPARγ agonist, cardiomyocytes-specific PPARγ-null mice display serious cardiac hypertrophy and cardiac dysfunction, indicating the indirect hypertrophic effect of PPARγ agonists (Duan et al., 2005). This evidence concerns the gene PPARG and cardiac hypertrophy.